Medical Policy and Coding Updates - April 2024
Premera HMO medical policies were revised effective April 1, 2024 for drugs including Padcev, Braftovi, Imbruvica, Jaypirca, generic gefitinib, Injectafer, Zelsuvmi and Vabysmo, and new policies made total facet arthroplasty for lumbar spinal stenosis and CO2 fractional laser ablation for hypertrophic scars and keloids investigational. Carelon Medical Benefits Management guideline updates for radiation therapy and advanced imaging apply to dates of service on and after April 14, 2024, and genetic testing updates apply to dates of service on and after June 30, 2024. Coding changes effective April 1, 2024 added codes that now require review for medical necessity, investigational status or prior authorization, moved Carelon Management Genetic Testing codes to Carelon review, and terminated codes including Q4244, C9160 and C9162.